In subcutaneously implanted tumor models, striking tumor regressions were observed in mice treated with the combination of VC and anti-PD-L1 in comparison to the single VC or anti-PD-L1 treatment (Fig. 9b, c), suggesting that VC augments PD-L1 checkpoint inhibitor-induced anti-tumor responses. This evidence concerns the gene CD274 and neoplasm.